145 related articles for article (PubMed ID: 29278101)
1. Bayesian hidden Markov models for delineating the pathology of Alzheimer's disease.
Kang K; Cai J; Song X; Zhu H
Stat Methods Med Res; 2019 Jul; 28(7):2112-2124. PubMed ID: 29278101
[TBL] [Abstract][Full Text] [Related]
2. Bayesian adaptive group lasso with semiparametric hidden Markov models.
Kang K; Song X; Hu XJ; Zhu H
Stat Med; 2019 Apr; 38(9):1634-1650. PubMed ID: 30484887
[TBL] [Abstract][Full Text] [Related]
3. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
[TBL] [Abstract][Full Text] [Related]
5. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
[TBL] [Abstract][Full Text] [Related]
6. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers.
Schuff N; Woerner N; Boreta L; Kornfield T; Shaw LM; Trojanowski JQ; Thompson PM; Jack CR; Weiner MW;
Brain; 2009 Apr; 132(Pt 4):1067-77. PubMed ID: 19251758
[TBL] [Abstract][Full Text] [Related]
7. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.
Jack CR; Wiste HJ; Vemuri P; Weigand SD; Senjem ML; Zeng G; Bernstein MA; Gunter JL; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS;
Brain; 2010 Nov; 133(11):3336-48. PubMed ID: 20935035
[TBL] [Abstract][Full Text] [Related]
8. Dynamic predictions in Bayesian functional joint models for longitudinal and time-to-event data: An application to Alzheimer's disease.
Li K; Luo S
Stat Methods Med Res; 2019 Feb; 28(2):327-342. PubMed ID: 28750578
[TBL] [Abstract][Full Text] [Related]
9. Disease progression modeling using Hidden Markov Models.
Sukkar R; Katz E; Zhang Y; Raunig D; Wyman BT
Annu Int Conf IEEE Eng Med Biol Soc; 2012; 2012():2845-8. PubMed ID: 23366517
[TBL] [Abstract][Full Text] [Related]
10. A joint model for multivariate longitudinal and survival data to discover the conversion to Alzheimer's disease.
Kang K; Pan D; Song X
Stat Med; 2022 Jan; 41(2):356-373. PubMed ID: 34726280
[TBL] [Abstract][Full Text] [Related]
11. Design and sample size considerations for Alzheimer's disease prevention trials using multistate models.
Brookmeyer R; Abdalla N
Clin Trials; 2019 Apr; 16(2):111-119. PubMed ID: 30922116
[TBL] [Abstract][Full Text] [Related]
12. Lack of reliable evidence for a distinctive ε4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study.
Foster JK; Albrecht MA; Savage G; Lautenschlager NT; Ellis KA; Maruff P; Szoeke C; Taddei K; Martins R; Masters CL; Ames D;
Brain; 2013 Jul; 136(Pt 7):2201-16. PubMed ID: 23737466
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis of Cognitive Impairment Compatible with Early Diagnosis of Alzheimer's Disease. A Bayesian Network Model based on the Analysis of Oral Definitions of Semantic Categories.
Guerrero JM; Martínez-Tomás R; Rincón M; Peraita H
Methods Inf Med; 2016; 55(1):42-9. PubMed ID: 25925692
[TBL] [Abstract][Full Text] [Related]
14. The contribution of vascular risk factors in neurodegenerative disorders: from mild cognitive impairment to Alzheimer's disease.
Cheng YW; Chiu MJ; Chen YF; Cheng TW; Lai YM; Chen TF
Alzheimers Res Ther; 2020 Aug; 12(1):91. PubMed ID: 32753051
[TBL] [Abstract][Full Text] [Related]
15. Fibre-specific white matter reductions in Alzheimer's disease and mild cognitive impairment.
Mito R; Raffelt D; Dhollander T; Vaughan DN; Tournier JD; Salvado O; Brodtmann A; Rowe CC; Villemagne VL; Connelly A
Brain; 2018 Mar; 141(3):888-902. PubMed ID: 29309541
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers for Early Diagnostic of Mild Cognitive Impairment in Type-2 Diabetes Patients: A Multicentre, Retrospective, Nested Case-Control Study.
Xu ZP; Yang SL; Zhao S; Zheng CH; Li HH; Zhang Y; Huang RX; Li MZ; Gao Y; Zhang SJ; Zhan PY; Zhang LF; Deng L; Wei S; Liu YC; Ye JW; Ren HJ; Li N; Kong CX; Wang X; Fang L; Zhou QZ; Jiang HW; Li JR; Wang Q; Ke D; Liu GP; Wang JZ
EBioMedicine; 2016 Mar; 5():105-13. PubMed ID: 27077117
[TBL] [Abstract][Full Text] [Related]
17. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.
Jack CR; Lowe VJ; Weigand SD; Wiste HJ; Senjem ML; Knopman DS; Shiung MM; Gunter JL; Boeve BF; Kemp BJ; Weiner M; Petersen RC;
Brain; 2009 May; 132(Pt 5):1355-65. PubMed ID: 19339253
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.
Vos SJ; Verhey F; Frölich L; Kornhuber J; Wiltfang J; Maier W; Peters O; Rüther E; Nobili F; Morbelli S; Frisoni GB; Drzezga A; Didic M; van Berckel BN; Simmons A; Soininen H; Kłoszewska I; Mecocci P; Tsolaki M; Vellas B; Lovestone S; Muscio C; Herukka SK; Salmon E; Bastin C; Wallin A; Nordlund A; de Mendonça A; Silva D; Santana I; Lemos R; Engelborghs S; Van der Mussele S; ; Freund-Levi Y; Wallin ÅK; Hampel H; van der Flier W; Scheltens P; Visser PJ
Brain; 2015 May; 138(Pt 5):1327-38. PubMed ID: 25693589
[TBL] [Abstract][Full Text] [Related]
19. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.
Gomar JJ; Bobes-Bascaran MT; Conejero-Goldberg C; Davies P; Goldberg TE;
Arch Gen Psychiatry; 2011 Sep; 68(9):961-9. PubMed ID: 21893661
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer's type.
Martino Adami PV; Orellana A; García P; Kleineidam L; Alarcón-Martín E; Montrreal L; Aguilera N; Espinosa A; Abdelnour C; Rosende-Roca M; Pablo Tartari J; Vargas L; Mauleón A; Esteban-De Antonio E; López-Cuevas R; Dalmasso MC; Campos Martin R; Parveen K; Andrade Fuentes VM; Amin N; Ahmad S; Ikram MA; Lewczuk P; Kornhuber J; Peters O; Frölich L; Rüther E; Wiltfang J; Tarraga L; Boada M; Maier W; de Rojas I; Cano A; Sanabria A; Alegret M; Hernández I; Marquié M; Valero S; van Duijn CM; Wagner M; Jessen F; Schneider A; Sáez Goñi ME; González Pérez A; Ruiz A; Ramírez A
Brain; 2022 Jul; 145(7):2507-2517. PubMed ID: 35088840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
